COMMUNIQUÉS West-GlobeNewswire

Advent International entre en négociations exclusives pour acquérir Zentiva, l'activité Génériques de Sanofi en Europe
17/04/2018
Communiqué de presse Source : Sanofi (EURONEXT : SAN) (NYSE : SNY) Advent International entre en négociations exclusives pour acquérir Zentiva, l'activité Génériques de Sanofi en Europe Advent va investir dans Zentiva [...]
CellaVision AB: The Nomination Committee of CellaVision AB supplements its proposal with an additional Board member
17/04/2018
The information was submitted to the public on April 17, 2018 at 8:20 CET The Nomination Committee presented its proposal to the Annual General Meeting on 4 May 2018 on April 4, 2018. The proposal and the motivated [...]
Posting of UK Annual Report and Accounts & Notice of AGM
17/04/2018
NEW YORK, April 17, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ: MTFB ), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that its 2017 UK Annual [...]
Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials
17/04/2018
Company to invest more than USD 100 million to advance research and development of new antimalarials over the next five years Commitment includes expanding access to pediatric antimalarials and implementing capacity- [...]
Novartis renouvelle son engagement afin d'éliminer le paludisme en investissant 100 millions de dollars dans la recherche et le développement d'antipaludiques de nouvelle génération
17/04/2018
L'entreprise s'apprête à investir plus de 100 millions de dollars afin de faire progresser la recherche et le développement de nouveaux antipaludiques au cours des cinq prochaines années L'engagement inclut également l' [...]
Basilea licenses late-stage oncology drug candidate derazantinib from ArQule
17/04/2018
Basel, Switzerland, April 17, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has entered into a license agreement with ArQule, Inc. (NASDAQ: ARQL) for its oncology drug candidate ARQ 087 ( [...]
Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program
17/04/2018
Company Release no. 10/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 17 April 2018 Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program Today, the Board of Directors of Veloxis [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
17/04/2018
REGULATED INFORMATION GHENT, Belgium, 17 April 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]
INNATE PHARMA : AACR 2018, New preclinical data further support ongoing programs
17/04/2018
new preclinical data further support ongoing programs and highlight next generation of immunotherapies Next generation of immunotherapies presented by Chief Scientific Officer Eric Vivier in a meet-the-expert session at [...]
INNATE PHARMA : AACR 2018 Nouvelles données précliniques renforçant le rationnel des programmes en cours
17/04/2018
NOUVELLES DONNEES PRECLINIQUES RENFORÇANT LE RATIONNEL DES PROGRAMMES EN COURS POUR UNE PROCHAINE GENERATION D'IMMUNOTHERAPIES Prochaine génération d'immunothérapies présentée par Eric Vivier, Directeur Scientifique, [...]
Novartis tender offer for AveXis commences
17/04/2018
Basel, April 17, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced that its indirect wholly-owned subsidiary, Novartis AM Merger Corporation, a Delaware corporation ("Purchaser"), has commenced a cash tender [...]
REVA to Present Full Two-Year FANTOM II Data at EuroPCR
17/04/2018
SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, announced that it will be presenting two- [...]
Apellis Pharmaceuticals Announces Proposed Offering of Common Stock
16/04/2018
CRESTWOOD, Ky. and WALTHAM, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS ), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds [...]
Boston Marathon Athlete Attempting to Break the Guinness World Record for the Fastest Marathon Ever Run Backwards Finishes Race in 5 Hours, 43 Minutes, 59 Seconds
16/04/2018
BOSTON, April 16, 2018 (GLOBE NEWSWIRE) -- Los Angeles native and Disney movie production lawyer, Loren Zitomersky (aka “The Backwards Guy”), attempted to break the Guinness World Record for the fastest marathon ever [...]
Advanced Proteome Therapeutics Announces Appointment of New Board Members
16/04/2018
VANCOUVER, British Columbia, April 16, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“ APC ” or the “ Company ”) (TSXV:APC) (FSE:0E8) is pleased to announce the appointments of Dr. John R. Garrett [...]
Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock
16/04/2018
HOUSTON, April 16, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM ), a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and [...]
Mateon Therapeutics Provides Business Update and Reports 2017 Financial Results
16/04/2018
SOUTH SAN FRANCISCO, Calif., April 16, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, [...]
HTG Promotes John Lubniewski to President and Chief Operating Officer
16/04/2018
Mr. Lubniewski assumes the role after having served for seven years as Chief Business Officer TUCSON, Ariz., April 16, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM ), a provider of instruments [...]
Mateon Therapeutics Raises Net Proceeds of Approximately $2.4 Million in Financing Transaction
16/04/2018
SOUTH SAN FRANCISCO, Calif., April 16, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc . (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, [...]

Pages